An investigational vaccine that targets common KRAS mutations induced durable immune responses among individuals at high risk ...
The vaccine spurs a lasting immune response in people at a high risk for pancreatic cancer. Whether it staves off the disease remains to be seen.
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive cancer that is often diagnosed at advanced stages and carries a low ...
Phase 1 clinical trial results of a KRAS-targeting vaccine for pancreatic ductal adenocarcinoma show it is safe and can ...
A first-in-human KRAS-targeted pancreatic cancer vaccine elicited durable immune responses in 90% of participants, and slowed precancerous lesions.
He warned that most of the weight loss advice we get is "wrong" ...
A team of researchers in the US has conducted an initial experimental trial with 20 subjects to demonstrate that immunization ...
After a promising Phase I read out on mKRAS-VAX in patients with hereditary cancer predisposition and pancreatic lesions, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results